ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-ROR1 Antibody-drug Conjugate IM-1021

Its studies are mostly in Hematologic Neoplasms, led by Immunome.

Furthest: phase 1, since Feb 4, 20251 company-led study, 1 open or runningNext primary completion: May 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Immunome11 open or runningphase 1since Feb 4, 2025Feb 4, 2025May 2028phase 1 · NCT06823167

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 4, 2025First study: phase 1 study in Hematologic NeoplasmsFirst studyNCT06823167 · 190 planned · United States, Denmark, France and more

Ahead

  1. May 2028Primary completion: phase 1 study in Hematologic NeoplasmsNCT06823167

TargetBeta

ROR1 →read by rule
“An antibody-drug conjugate (ADC) composed of an immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) ”NCIt, by rule

Other programs on ROR1

ProgramCompanyFurthest phaseStudies
zilovertamab vedotinMerckphase 310
Anti-ROR1/Anti-CD3 Bispecific Antibody EMB-07ruleshanghai-epimab-biotherapeutics-co-ltdphase 22
TQB2101Sino Biopharmaceuticalphase 12
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleneok-bio-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06823167Hematologic Neoplasms · United States, Denmark, France and more1RecruitingMay 2028190

How it is read

Names in the registry

  • “IM-1021”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.